ClinicalTrials.gg

Program

tenofovir amibufenamide

Also written as “HS-10234”, “Tenofovir Amibufenamide(TMF)” and “Tenofovir Amibufenamide(TMF)”.

Its studies are mostly in Hepatitis B, Chronic, led by 2 companies.

Furthest: phase 4, since Dec 13, 20244 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group31 open or runningphase 4since Dec 13, 2024Mar 3, 2019none ahead
GNI Group10 open or runningphase 1since Dec 10, 2025Dec 10, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 3, 2019First study: phase 3 study in Chronic HBV InfectionNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT03903796 · 963 enrolled · China
  2. Jul 14, 2020Phase 1 study in Healthy SubjectsHansoh Pharmaceutical Group · NCT04477096 · 36 enrolled · China
  3. Dec 13, 2024Phase 4 study in Hepatitis B, ChronicHansoh Pharmaceutical Group · NCT06743438 · 640 enrolled · China
  4. Dec 10, 2025GNI Group’s first study: phase 1 study in Chronic Hepatitis B Liver FibrosisNew to GNI GroupGNI Group · NCT07295873 · 64 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07295873Chronic Hepatitis B Liver Fibrosis · China1CompletedGNI GroupMay 29, 202664
NCT06743438Hepatitis B, Chronic · China4Active, not recruitingHansoh Pharmaceutical GroupJun 30, 2024640
NCT04477096Healthy Subjects · China1CompletedHansoh Pharmaceutical GroupSep 24, 202036
NCT03903796Chronic HBV Infection · China3CompletedHansoh Pharmaceutical GroupMay 31, 2020963

How it is read

Names in the registry

  • “HS-10234”, 2 entries
  • “Tenofovir Amibufenamide(TMF)”, 1 entry
  • “Tenofovir Amibufenamide(TMF)”, 1 entry

Codes read as this program: HS10234.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
tenofovir amibufenamide (Hansoh Pharmaceutical Group): development program | ClinicalTrials.gg